Fusion genes associated with progressive prostate cancer

Patent metadata

Field	Value
Publication number	US-10988812-B2
Application number	US-201916425355-A
Country	US
Kind code	B2
Filing date	May 29, 2019
Priority date	Dec 30, 2013
Publication date	Apr 27, 2021
Grant date	Apr 27, 2021

Abstract

The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.

First claim

What is claimed is:

1. A method of treating a subject in need thereof, comprising (i) determining whether a subject is at increased risk of manifesting progressive prostate cancer comprising determining whether a prostate cancer cell of the subject contains a PTEN-NOLC1 or CCNH-C5orf30 fusion gene; and (ii) where the prostate cancer cell contains the PTEN-NOLC1 or CCNH-C5orf30 fusion gene so that the subject is at increased risk, then performing one or more of cryotherapy, radiation therapy, chemotherapy, hormone therapy, and radical prostatectomy to treat the subject.

2. The method of claim 1 , wherein the fusion gene is detected by fluorescence in situ hybridization (FISH) analysis.

3. The method of claim 1 , wherein the fusion gene is detected by polymerase chain reaction (PCR).

4. The method of claim 1 , wherein the fusion gene is detected by Western blot analysis.

5. The method of claim 1 , wherein the subject is determined to be at increased risk of rapid relapse.

6. The method of claim 1 , wherein the subject is determined to be at increased risk of relapse.

7. The method of claim 1 , further comprising determining a nomogram score of the subject.

8. The method of claim 1 , wherein the fusion gene is PTEN-NOLC1.

9. The method of claim 1 , wherein the fusion gene is CCNH-C5orf30.

10. A method of treating a subject, comprising:
(i) determining whether a subject is at increased risk of manifesting progressive prostate cancer comprising determining whether a prostate cancer cell of the subject contains a PTEN-NOLC1 or CCNH-C5orf30 fusion gene; and
(ii) where the cell contains the PTEN-NOLC1 or CCNH-C5orf30 fusion gene so that the subject is at increased risk, perform at least one of the following steps;
(a) administering a therapeutically effective amount of an inhibitor of the PTEN-NOLC1 or CCNH-C5orf30 fusion protein to the subject, wherein the inhibitor specifically binds to and inhibits and/or reduces activity of the fusion protein;
(b) administering a therapeutically effective amount of an agent that inhibits the PTEN-NOLC1 or CCNH-C5orf30 fusion protein to the subject, wherein the agent specifically binds to and inhibits and/or reduces activity of the fusion protein;
(c) administering a therapeutically effective amount of an siRNA targeting the PTEN-NOLC1 or CCNH-C5orf30 fusion gene contained within the prostate cancer cell to the subject;
(d) administering a therapeutically effective amount of an anti-cancer agent selected from the group consisting of chemotherapeutic agents, radiotherapeutic agents, cytokines, anti-angiogenic agents, apoptosis-inducing agents, and anti-cancer immunotoxins to the subject; and/or
(e) performing a targeted genome editing procedure on one or more prostate cancer cells within the subject.

11. The method of claim 10 , wherein the fusion gene is detected by fluorescence in situ hybridization (FISH) analysis.

12. The method of claim 10 , wherein the fusion gene is detected by polymerase chain reaction (PCR).

13. The method of claim 10 , wherein the fusion gene is detected by Western blot analysis.

14. The method of claim 10 , wherein the subject is determined to be at increased risk of rapid relapse.

15. The method of claim 10 , wherein the subject is determined to be at increased risk of relapse.

16. The method of claim 10 , wherein the fusion gene is PTEN-NOLC1.

17. The method of claim 10 , wherein the fusion gene is CCNH-C5orf30.

18. The method of claim 10 , wherein a therapeutically effective amount of an inhibitor of the PTEN-NOLC1 or CCNH-C5orf30 fusion protein is administered.

19. The method of claim 10 , wherein a targeted genome editing procedure is performed on one or more prostate cancer cells within the subject.

Assignees

• Univ Pittsburgh Commonwealth Sys Higher Education

Inventors

• Luo Jianhua
• Yu Yangping
• Nelson Joel B
• Michalopoulos George Konstantine
• Tseng Chien-Cheng
• Ding Ying

Classifications

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title